# Entera Bio Ltd. (ENTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.00, market value $519 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Entera Bio Ltd. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 20.4×**. The shares trade at 20.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.1%** (5-yr avg -26.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -87.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -115.1%**. Return on all capital, debt included, is -115.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -106.5%**. Each dollar of assets produces -106.5% of profit.

## Growth
- **Revenue growth (1 yr): -76.8%** (3-yr -32.1%/yr, 5-yr -35.1%/yr). Revenue fell 76.8% over the last year, against -35.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 0.0%** (3-yr -17.8%/yr, 5-yr -14.6%/yr). Earnings per share rose 0.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.30**. Debt is 0.30 times equity: a conservative balance sheet.
- **Current ratio: 6.94** (quick 6.94). Current assets cover the next year's liabilities 6.94 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Entera Bio Ltd. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 38.9%** (YTD 54.6%, 3-mo 154.2%). The shares are up 38.9% over twelve months including dividends.
- **From 52-week high: -28.6%** (229.7% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.72** (volatility 129%). Beta of 0.72 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ENTX · Page: https://foliofundamentals.com/stocks/entx

Not investment advice.